Shareholders of Burcon NutraScience (TSE:BU) approved all matters presented at the company’s annual general and special meeting, including the re-election of six directors, the re-approval of its share option plan and resolutions connected to a proposed convertible debenture financing of up to C$21 million.
Chairman Peter Kappel said shareholders elected Alan Chan, Kappel, John Vassallo, James Peter Pekar, Philip Dowad and Chris Bunio to serve until the next annual meeting or until successors are elected or appointed. Shareholders also approved the appointment of KPMG LLP as auditor and authorized the board to set the auditor’s compensation.
Convertible Debenture Financing Approved
Burcon obtained the required approvals related to its planned private placement of convertible debentures, which the company announced Sept. 4. The financing is expected to raise up to C$21 million.
Shareholders approved the potential issuance of up to 13.125 million common shares upon conversion of the debentures, including shares issuable through pre-funded warrants. Disinterested shareholders also approved the potential issuance of up to 3.694 million common shares to insiders and other related parties upon conversion of their debentures.
The disinterested approval also covered up to C$3.546 million in interest payments to insiders and other related parties participating in the financing. Kappel said votes held by participating insiders and their affiliates and associates were excluded from that vote.
Chief Executive Officer Kip Underwood said the financing has support from board insiders, one of Burcon’s largest institutional investors and other market participants. He said the company expects the financing to close “in the near term,” potentially within the next several weeks following shareholder approval.
Underwood said proceeds are expected to be used primarily to expand production and sales capabilities, strengthen facility reliability, support working capital and add operational capacity. He cited maintenance staffing, critical spare parts and additional utility redundancy involving steam, water and power as areas of focus.
Protein Demand and Commercial Pipeline
Underwood said Burcon sees growing demand for protein-fortified foods, which he attributed primarily to increased use of GLP-1 weight-management medications. He said users of those medications require more protein in their diets and that consumers increasingly want protein-enhanced products without sacrificing taste, convenience, flavor or appearance.
He described the protein-fortified food market as a C$17 billion to C$20 billion market with estimated growth of 8% to 10% annually. Underwood said rising demand has created capacity constraints for dairy-based proteins, including whey, and that Burcon’s plant-based proteins can provide dairy-like performance at a lower overall cost than dairy alternatives.
Burcon has launched four proteins at commercial scale:
- Supertein sunflower protein
- Peazazz protein
- FavaPro fava protein
- Puratein canola protein
Underwood said the products can support claims including high protein, plant-based, non-GMO, egg-free, dairy-free and vegan. He said Burcon’s technology platform, developed over 20 years, focuses on purification intended to reduce unwanted color, flavors and aromas in finished food products.
The company currently has more than 40 buying customers and more than 209 active customer projects, according to Underwood. He said food-product development and reformulation projects generally take between nine and 24 months to move through commercialization.
Burcon has 36 customers that have progressed beyond purchasing an initial bag of product, he said, and 26 customers that have bought pallet-sized quantities and could progress toward half-truckload orders. Underwood characterized customers purchasing half-truckload or truckload volumes as potential anchor accounts.
Revised 2026 Outlook
Underwood said recent facility reliability issues affected production and created a slight delay in sales, though the company has implemented solutions. The company is raising capital in part to make those solutions more robust as it scales production.
Burcon revised its outlook and now expects to deliver C$6 million in sales during 2026 and exit the calendar year at a C$10 million revenue run rate. Underwood said the company anticipates becoming cash-flow positive during calendar 2027.
He said much of Burcon’s fixed-cost investment should be completed by the end of 2026, allowing a larger portion of future revenue growth to contribute to profitability. The company remains focused on sales and production from its current facility, while viewing future technology licensing as a longer-term opportunity after it strengthens its financial position, validates customer demand and demonstrates margins at commercial scale.
Underwood said Burcon has received interest from potential licensing partners but plans to prioritize capacity expansion and execution of its current strategy before pursuing such discussions more actively.
About Burcon NutraScience (TSE:BU)
Burcon is a global technology leader in plant-based proteins for food and beverage applications. The Company has developed a portfolio of high-performance protein ingredients, including Peazzaz® pea proteins, FavaPro TM fava proteins and Puratein® canola proteins, and is focused on commercializing its technologies through manufacturing partnerships and growing customer adoption worldwide.
